ID: ALA2373039

Max Phase: Preclinical

Molecular Formula: C26H39N9O7

Molecular Weight: 589.65

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(C)[C@@H]1NC(=O)[C@H](CCCN=C(N)N)NC(=O)NNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccccc2)N(C)C1=O

Standard InChI:  InChI=1S/C26H39N9O7/c1-14(2)20-24(41)35(3)18(12-15-8-5-4-6-9-15)23(40)30-17(13-19(36)37)22(39)33-34-26(42)31-16(21(38)32-20)10-7-11-29-25(27)28/h4-6,8-9,14,16-18,20H,7,10-13H2,1-3H3,(H,30,40)(H,32,38)(H,33,39)(H,36,37)(H4,27,28,29)(H2,31,34,42)/t16-,17-,18-,20-/m0/s1

Standard InChI Key:  LLJAASOTTFNJHX-JPLJXNOCSA-N

Associated Targets(Human)

ITGB3 Tclin Integrin alpha-V/beta-3 (2708 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ITGB3 Tclin Integrin alpha-V/beta-3 and alpha-IIb/beta 3 (49 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 589.65Molecular Weight (Monoisotopic): 589.2972AlogP: -2.08#Rotatable Bonds: 9
Polar Surface Area: 250.44Molecular Species: ZWITTERIONHBA: 7HBD: 8
#RO5 Violations: 2HBA (Lipinski): 16HBD (Lipinski): 10#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.95CX Basic pKa: 10.28CX LogP: -3.55CX LogD: -3.55
Aromatic Rings: 1Heavy Atoms: 42QED Weighted: 0.09Np Likeness Score: 1.10

References

1. Sulyok GA, Gibson C, Goodman SL, Hölzemann G, Wiesner M, Kessler H..  (2001)  Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.,  44  (12): [PMID:11384239] [10.1021/jm0004953]

Source